[A25-156] Iptacopan (paroxysmal nocturnal haemoglobinuria) – Benefit assessment according to §35a Social Code Book V
Last updated 16.03.2026
Project no.:
A25-156
Commission:
Commission awarded on 15.12.2025 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Haematology
Indication:
Adults with paroxysmal nocturnal haemoglobinuria (PNH)
Result of dossier assessment:
- Patients with haemolytic anaemia who are treatment-naive: added benefit not proven
- Patients who still have haemolytic anaemia and have received prior treatment: added benefit not proven
Note:
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
DOI:
https://doi.org/10.60584/A25-156
| Project no. | Title | Status |
|---|---|---|
| A25-157 | Iptacopan (complement 3 glomerulopathy) – Benefit assessment according to §35a Social Code Book V | Commission completed |
| G25-16 | Iptacopan (complement 3 glomerulopathy) – Assessment according to §35a (para. 1, sentence 11) Social Code Book V | Commission completed |
| G24-16 | Iptacopan (paroxysmal nocturnal haemoglobinuria with haemolytic anaemia) – Assessment according to §35a SGB V (1), Sentence 11 | Commission completed |